Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12617000239369
Ethics application status
Approved
Date submitted
6/02/2017
Date registered
16/02/2017
Date last updated
16/02/2017
Type of registration
Prospectively registered
Titles & IDs
Public title
The effects of spinal cord stimulation on nerve function in low back pain
Query!
Scientific title
The long-term effects of spinal cord stimulation on neural function in chronic low back pain – a pilot study
Query!
Secondary ID [1]
290747
0
Nil known.
Query!
Universal Trial Number (UTN)
U1111-1190-9161
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Lower back pain
301334
0
Query!
Condition category
Condition code
Musculoskeletal
301087
301087
0
0
Query!
Other muscular and skeletal disorders
Query!
Neurological
301587
301587
0
0
Query!
Other neurological disorders
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
False
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
Prior to their enrolment in this study participants will have been assessed as being suitable candidates, as part of their usual medical care, for either a high frequency (10kHz) spinal cord stimulator (SCS) or a low frequency (100Hz) SCS. Assignment to either high frequency SCS or to low frequency SCS occurs as part of a participants usual medical care and does not form part of this trial.
Arm 1: Participants with lower back pain who successfully completed a trial implantation and proceeded to have a low frequency SCS fitted.
Arm 2: Participants with lower back pain who successfully completed a trial implantation and proceeded to have a high frequency SCS fitted.
Participants in Arms 1 and 2 will be enrolled and followed up from approximately two weeks prior to a temporary SCS implantation until a time point 12 months after the implantation of a permanent SCS.
Query!
Intervention code [1]
297077
0
Not applicable
Query!
Comparator / control treatment
The control group will consist of participants with lower back pain who, as part of their usual medical care, were assessed as being suitable candidates for a trial of either low or high frequency SCS but in whom the trial was unsuccessful and therefore the participants did not proceed to permanent fitment of a spinal cord stimulator.
Participants will be enrolled and followed up from approximately two weeks prior to a temporary SCS implantation until a time point 12 months after the removal of the trial SCS.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
300977
0
Change in sensitivity to vibratory stimuli when compared to the pre implantation measure.
Vibration sensitivity will be assessed using a standard Rydel-Seiffer tuning fork and also a Medoc VSA-3000 vibrameter.
Query!
Assessment method [1]
300977
0
Query!
Timepoint [1]
300977
0
Baseline and twelve months post permanent SCS implantation.
Query!
Secondary outcome [1]
331313
0
Change in sensitivity to vibratory stimuli at 2 weeks, 2 months and six months post implantation, when compared to the baseline score.
Vibration sensitivity will be assessed using a standard Rydel-Seiffer tuning fork and also a Medoc VSA-3000 vibrameter.
Query!
Assessment method [1]
331313
0
Query!
Timepoint [1]
331313
0
2 weeks, 2 months and 6 months post permanent SCS implantation.
Query!
Eligibility
Key inclusion criteria
1. Have a primary diagnosis of chronic low back pain (lumbo-sacral) with or without leg pain.
2. Be a candidate for a commercial spinal cord stimulation system.
3. Have responded inadequately to at least 6 months of conservative treatment (pharmacological, physical therapy +/- spinal injections including radiofrequency lesioning).
4. Pain intensity >= 3/10 (NRS11) over previous month.
5. Patients may have had previous spinal surgery.
6. Patients with a known condition that may potentially result in neuropathy will not be excluded (e.g. diabetes, multiple sclerosis).
7. Patients with a significant neuropathy demonstrated on clinical examination (e.g. reflex depression, focal sensory changes or focal muscle weakness, especially lower limbs) will not be excluded.
8. May have undertaken a cognitive behavioural therapy pain program.
9. Be able to consent.
10. Be 18 years or older at the time of enrolment.
11. Be able to comply with study procedures.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Have mechanical spinal instability (diagnosed with radiological imaging).
2. Have malignancy with life expectancy <1year.
3. Have a systemic infection.
4. Have other implantable devices.
5. Are participating in another clinical trial.
6. Have unstable major psychiatric comorbidities.
7. Are pregnant/lactating or not using adequate birth control.
8. Have bleeding or coagulopathy issues.
9. Are immunocompromised and at risk of infection.
10. Have uncontrolled insulin-dependent diabetes mellitus despite treatment.
Query!
Study design
Purpose
Natural history
Query!
Duration
Longitudinal
Query!
Selection
Defined population
Query!
Timing
Prospective
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
31/03/2017
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
30
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Funding & Sponsors
Funding source category [1]
295530
0
Other Collaborative groups
Query!
Name [1]
295530
0
Australia and New Zealand College of Anaesthetists
Query!
Address [1]
295530
0
ANZCA House,
630 St Kilda Road,
Melbourne, Victoria 3004,
Australia.
Query!
Country [1]
295530
0
Australia
Query!
Primary sponsor type
Government body
Query!
Name
Northern Sydney Local Health District
Query!
Address
Royal North Shore Hospital, Reserve Road, St Leonards, NSW 2065
Query!
Country
Australia
Query!
Secondary sponsor category [1]
294348
0
None
Query!
Name [1]
294348
0
Query!
Address [1]
294348
0
Query!
Country [1]
294348
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
296851
0
NSLHD HREC
Query!
Ethics committee address [1]
296851
0
Level 13, Kolling Building, Royal North Shore Hospital, Reserve Road, St leonards, NSW 2065
Query!
Ethics committee country [1]
296851
0
Australia
Query!
Date submitted for ethics approval [1]
296851
0
30/09/2016
Query!
Approval date [1]
296851
0
20/10/2016
Query!
Ethics approval number [1]
296851
0
HREC/16/HAWKE/287
Query!
Summary
Brief summary
Spinal cord stimulation (SCS) has been employed for the management of chronic pain for over 50 years. Over this time SCS has become a well-established mode of treatment for neuropathic pain. Until recently most success with SCS has been obtained with pain involving the limbs (e.g. CRPS, sciatica, ischaemic limb pain and peripheral neuropathy). Relief of axial back pain has been more difficult to achieve. In response to problems associated with SCS (stimulation variance with body position, MRI lead incompatibility, difficulties covering certain pain sites) a wide range of device options have developed. As a result the number of companies manufacturing implantable spinal cord stimulators continues to increase with each company claiming specific benefits for their device range.
The most dramatic recent change has been the introduction of high frequency (HF) SCS (500 Hz to 10,000 Hz). Early work on HF SCS demonstrated potential benefits on axial back pain. The additional feature of “paraesthesia-free” stimulation to avoid the need for paraesthesias required by the more conventional tonic low frequency (LF) SCS (<100Hz) has made this form of stimulation more attractive. Paraesthesias have the potential for discomfort particularly with changes in position (standing to lying). In 2015, a landmark prospective randomised trial was published (Kapural et al) reporting superiority of HF SCS over LF SCS for axial back pain. While the mechanisms of action for conventional SCS are still being investigated, even less is known about HF stimulation. Given the positive results reported by Kapural et al it is likely that the use of HF SCS will dramatically increase. While no definitive evidence of neural damage has been found on clinical examination concern has been raised in animal studies about the potential for long-term neural changes with HF SCS. In addition certain patient subpopulations may be more vulnerable to stimulation induced changes in neural function particularly those with spinal canal stenosis (personal communication). Given Kapural et al has only recently been published consensus regarding the long-term use of HF SCS in axial low back pain is yet to be reached.
This pilot study will monitor changes in neural function associated with propriety LF (<100Hz) and HF (10kHz) SCS implantation in people with chronic low back pain over twelve months. The project will inform the development of a full-scale trial. The Global Burden of Disease study now ranks low back pain (LBP) as the number one cause of disability in Australasia. Three million Australians now have long-term disability due to chronic LBP, costing more than $14 billion each year.
As a result of a recent successful high profile multi-centre trial HF SCS implantation for chronic LBP is likely to increase. It is crucial therefore to obtain long-term safety data on this treatment to better inform patient selection and future cost benefit analyses.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
71162
0
Dr Paul Wrigley
Query!
Address
71162
0
Level 13, Kolling Building, Royal North Shore Hospital, Reserve Road, St Leonards, NSW 2065
Query!
Country
71162
0
Australia
Query!
Phone
71162
0
+61 2 9926 4958
Query!
Fax
71162
0
Query!
Email
71162
0
[email protected]
Query!
Contact person for public queries
Name
71163
0
Dr Paul Wrigley
Query!
Address
71163
0
Level 13, Kolling Building, Royal North Shore Hospital, Reserve Road, St Leonards, NSW 2065
Query!
Country
71163
0
Australia
Query!
Phone
71163
0
+61 2 9926 4958
Query!
Fax
71163
0
Query!
Email
71163
0
[email protected]
Query!
Contact person for scientific queries
Name
71164
0
Dr Paul Wrigley
Query!
Address
71164
0
Level 13, Kolling Building, Royal North Shore Hospital, Reserve Road, St Leonards, NSW 2065
Query!
Country
71164
0
Australia
Query!
Phone
71164
0
+61 2 9926 4958
Query!
Fax
71164
0
Query!
Email
71164
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
Current Study Results
No documents have been uploaded by study researchers.
Update to Study Results
Doc. No.
Type
Is Peer Reviewed?
DOI
Citations or Other Details
Attachment
4039
Plain language summary
No
A sub study looking at ways of accurately and reli...
[
More Details
]
4642
Study results article
Yes
03/11/2018 https://onlinelibrary.wiley.com/doi/f...
[
More Details
]
Documents added automatically
No additional documents have been identified.
Download to PDF